Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Parenterally Administered VH4524184 in Healthy Adults
NCT06310551Phase 1Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Mar 2024
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VH4524184 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by ViiV Healthcare. Primary endpoints: Adverse Events at Week 80, Adverse Events by Severity at Week 80 and 17 more. Started Mar 2024; status: recruiting.
02
Drugs
VH4524184
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06310551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310551.